• 34211 Citations
  • 69 h-Index
19972019
If you made any changes in Pure these will be visible here soon.

Research Output 1997 2019

2019

Accumulation of Circulating CCR7+ Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway

Cristiani, C. M., Turdo, A., Ventura, V., Apuzzo, T., Capone, M., Madonna, G., Mallardo, D., Garofalo, C., Giovannone, E. D., Grimaldi, A. M., Tallerico, R., Marcenaro, E., Pesce, S., Zotto, G. D., Agosti, V., Costanzo, F. S., Gulletta, E., Rizzo, A., Moretta, A., Karre, K. & 3 others, Ascierto, P. A., Todaro, M. & Carbone, E., May 2019, In : Cancer immunology research. 7, 5, p. 841-852 12 p.

Research output: Contribution to journalArticle

Natural Killer Cells
Melanoma
Galectins
Neoplastic Stem Cells
T-Lymphocyte Subsets
1 Citation (Scopus)

Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial

Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J. J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., Lebbe, C., Ferraresi, V., Smylie, M., Weber, J. S., Maio, M., Hosein, F., de Pril, V., Kicinski, M., Suciu, S. & Testori, A., Sep 1 2019, In : European Journal of Cancer. 119, p. 1-10 10 p.

Research output: Contribution to journalArticle

Melanoma
Placebos
Survival
Neoplasm Metastasis
Recurrence
2 Citations (Scopus)

Adverse events 2.0—Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology

Heinzerling, L., Ascierto, P. A., Dummer, R., Gogas, H., Grob, J. J., Lebbe, C., Long, G. V., McArthur, G., Moslehi, J. J., Neilan, T. G., Ribas, A., Robert, C., Schadendorf, D., Wolchok, J. D. & Hauschild, A., May 1 2019, In : European Journal of Cancer. 112, p. 29-31 3 p.

Research output: Contribution to journalLetter

Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management

Gogas, H. J., Flaherty, K. T., Dummer, R., Ascierto, P. A., Arance, A., Mandala, M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsova, I., Gutzmer, R., Sileni, V. C., Dutriaux, C., de Groot, J. W. B., Yamazaki, N., Loquai, C., Gollerkeri, A., Pickard, M. D. & Robert, C., Sep 1 2019, In : European Journal of Cancer. 119, p. 97-106 10 p.

Research output: Contribution to journalArticle

Open Access
Cohort Studies
Mitogen-Activated Protein Kinase Kinases
Melanoma
encorafenib
MEK162
10 Citations (Scopus)

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable

Cortellini, A., Bersanelli, M., Buti, S., Cannita, K., Santini, D., Perrone, F., Giusti, R., Tiseo, M., Michiara, M., Di Marino, P., Tinari, N., De Tursi, M., Zoratto, F., Veltri, E., Marconcini, R., Malorgio, F., Russano, M., Anesi, C., Zeppola, T., Filetti, M. & 25 others, Marchetti, P., Botticelli, A., Antonini Cappellini, G. C., De Galitiis, F., Vitale, M. G., Rastelli, F., Pergolesi, F., Berardi, R., Rinaldi, S., Tudini, M., Silva, R. R., Pireddu, A., Atzori, F., Chiari, R., Ricciuti, B., De Giglio, A., Iacono, D., Gelibter, A., Occhipinti, M. A., Parisi, A., Porzio, G., Fargnoli, M. C., Ascierto, P. A., Ficorella, C. & Natoli, C., Feb 27 2019, In : Journal for ImmunoTherapy of Cancer. 7, 1, 57.

Research output: Contribution to journalArticle

Open Access
Multicenter Studies
Body Mass Index
Neoplasms
Thinness
Renal Cell Carcinoma

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system

Larkin, J., Brown, M. P., Arance, A. M., Hauschild, A., Queirolo, P., Vecchio, M. D., Ascierto, P. A., Krajsová, I., Schachter, J., Neyns, B., Garbe, C., Sileni, V. C., Mandalà, M., Gogas, H., Espinosa, E., Hospers, G., Lorigan, P., Nyakas, M., Guminski, A., Liszkay, G. & 5 others, Rutkowski, P., Miller, W., Donica, M., Makrutzki, M. & Blank, C., Jan 2019, In : European Journal of Cancer. 107, p. 175-185 11 p.

Research output: Contribution to journalArticle

Multicenter Studies
Melanoma
Safety
Mutation
PLX4032

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma

Larkin, J., Brown, M. P., Arance, A. M., Hauschild, A., Queirolo, P., Vecchio, M. D., Ascierto, P. A., Krajsová, I., Schachter, J., Neyns, B., Garbe, C., Sileni, V. C., Mandalà, M., Gogas, H., Espinosa, E., Hospers, G., Lorigan, P., Nyakas, M., Guminski, A., Liszkay, G. & 5 others, Rutkowski, P., Miller, W., Donica, M., Makrutzki, M. & Blank, C., Jan 2019, In : European Journal of Cancer. 107, p. 175-185 11 p.

Research output: Contribution to journalArticle

Multicenter Studies
Melanoma
Safety
Mutation
PLX4032
2 Citations (Scopus)

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system

Larkin, J., Brown, M. P., Arance, A. M., Hauschild, A., Queirolo, P., Vecchio, M. D., Ascierto, P. A., Krajsová, I., Schachter, J., Neyns, B., Garbe, C., Sileni, V. C., Mandalà, M., Gogas, H., Espinosa, E., Hospers, G., Lorigan, P., Nyakas, M., Guminski, A., Liszkay, G. & 5 others, Rutkowski, P., Miller, W., Donica, M., Makrutzki, M. & Blank, C., Jan 1 2019, In : European Journal of Cancer. 107, p. 175-185 11 p.

Research output: Contribution to journalArticle

Multicenter Studies
Melanoma
Safety
Mutation
PLX4032

A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients

Weide, B., Eigentler, T., Catania, C., Ascierto, P. A., Cascinu, S., Becker, J. C., Hauschild, A., Romanini, A., Danielli, R., Dummer, R., Trefzer, U., Elia, G., Neri, D. & Garbe, C., 2019, In : Cancer Immunology, Immunotherapy.

Research output: Contribution to journalArticle

Dacarbazine
Melanoma
Interleukin-2
Phase II Clinical Trials
Fibronectins

Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma

Harder, N., Schönmeyer, R., Nekolla, K., Meier, A., Brieu, N., Vanegas, C., Madonna, G., Capone, M., Botti, G., Ascierto, P. A. & Schmidt, G., Dec 1 2019, In : Scientific Reports. 9, 1, 7449.

Research output: Contribution to journalArticle

Open Access
Routine Diagnostic Tests
Melanoma
Tumor-Infiltrating Lymphocytes
Decision Trees
Precision Medicine
1 Citation (Scopus)

Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma

Van Herpen, C. M. L., Agarwala, S. S., Hauschild, A., Berking, C., Thaddeus Beck, J., Schadendorf, D., Jansen, R., Queirolo, P., Ascierto, P. A., Blank, C. U., Heinrich, M. C., Pal, R. R., Derti, A., Antona, V., Nauwelaerts, H., Zubel, A. & Dummer, R., Mar 1 2019, In : Oncotarget. 10, 19, p. 1850-1859 10 p.

Research output: Contribution to journalArticle

Melanoma
Biomarkers
Mitogen-Activated Protein Kinases
Mitogen-Activated Protein Kinase Kinases
Mutation

BRAF Mutations and Dysregulation of the MAP Kinase Pathway Associated to Sinonasal Mucosal Melanomas

Colombino, M., Paliogiannis, P., Cossu, A., De Re, V., Miolo, G., Botti, G., Scognamiglio, G., Ascierto, P. A., Santeufemia, D. A., Fraggetta, F., Manca, A., Sini, M. C., Casula, M., Palomba, G., Pisano, M., Doneddu, V., Lissia, A., Fedeli, M. A. & Palmieri, G., Oct 1 2019, In : Journal of Clinical Medicine. 8, 10

Research output: Contribution to journalArticle

Melanoma
Phosphotransferases
Mutation
Genes
Immune Tolerance

Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab

Quagliariello, V., Passariello, M., Coppola, C., Rea, D., Barbieri, A., Scherillo, M., Monti, M. G., Iaffaioli, R. V., De Laurentiis, M., Ascierto, P. A., Botti, G., De Lorenzo, C. & Maurea, N., 2019, In : International Journal of Cardiology.

Research output: Contribution to journalArticle

NF-kappa B
Leukotriene B4
Cardiac Myocytes
Interleukins
Immunotherapy
4 Citations (Scopus)

Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC

Antonia, S. J., Balmanoukian, A., Brahmer, J., Ou, S. H. I., Hellmann, M. D., Kim, S. W., Ahn, M. J., Kim, D. W., Gutierrez, M., Liu, S. V., Schöffski, P., Jäger, D., Jamal, R., Jerusalem, G., Lutzky, J., Nemunaitis, J., Calabrò, L., Weiss, J., Gadgeel, S., Bhosle, J. & 11 others, Ascierto, P. A., Rebelatto, M. C., Narwal, R., Liang, M., Xiao, F., Antal, J., Abdullah, S., Angra, N., Gupta, A. K., Khleif, S. N. & Segal, N. H., Oct 1 2019, In : Journal of Thoracic Oncology. 14, 10, p. 1794-1806 13 p.

Research output: Contribution to journalArticle

Open Access
Cell Death
Ligands
Safety
Disease-Free Survival
Pneumonia
4 Citations (Scopus)

Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study

Cortellini, A., Buti, S., Santini, D., Perrone, F., Giusti, R., Tiseo, M., Bersanelli, M., Michiara, M., Grassadonia, A., Brocco, D., Tinari, N., De Tursi, M., Zoratto, F., Veltri, E., Marconcini, R., Malorgio, F., Garufi, C., Russano, M., Anesi, C., Zeppola, T. & 25 others, Filetti, M., Marchetti, P., Botticelli, A., Antonini Cappellini, G. C., De Galitiis, F., Vitale, M. G., Sabbatini, R., Bracarda, S., Berardi, R., Rinaldi, S., Tudini, M., Silva, R. R., Pireddu, A., Atzori, F., Chiari, R., Ricciuti, B., Iacono, D., Migliorino, M. R., Rossi, A., Porzio, G., Cannita, K., Ciciarelli, V., Fargnoli, M. C., Ascierto, P. A. & Ficorella, C., 2019, In : Oncologist.

Research output: Contribution to journalArticle

Preexisting Condition Coverage
Immunotherapy
Autoimmune Diseases
Neoplasms
Incidence

Correction: New paradigm for stage III melanoma: From surgery to adjuvant treatment (Journal of Translational Medicine (2019) 17 (266) DOI: 10.1186/s12967-019-2012-2)

Ascierto, P. A., Borgognoni, L., Botti, G., Guida, M., Marchetti, P., Mocellin, S., Muto, P., Palmieri, G., Patuzzo, R., Quaglino, P., Stanganelli, I. & Caracò, C., Sep 18 2019, In : Journal of Translational Medicine. 17, 1, 315.

Research output: Contribution to journalComment/debate

Open Access
Translational Medical Research
Fluorouracil
Surgery
Medicine
Publications
Biological Factors
Antineoplastic Agents
clinical trials
Clinical Trials
Costs and Cost Analysis

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

Ascierto, P. A., Ferrucci, P. F., Fisher, R., Del Vecchio, M., Atkinson, V., Schmidt, H., Schachter, J., Queirolo, P., Long, G. V., Di Giacomo, A. M., Svane, I. M., Lotem, M., Bar-Sela, G., Couture, F., Mookerjee, B., Ghori, R., Ibrahim, N., Moreno, B. H. & Ribas, A., Jun 1 2019, In : Nature Medicine. 25, 6, p. 941-946 6 p.

Research output: Contribution to journalLetter

Melanoma
Placebos
Blocking Antibodies
Mitogen-Activated Protein Kinase Kinases
Transaminases

Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: An insight from clinical practice

Cortellini, A., Vitale, M. G., De Galitiis, F., Di Pietro, F. R., Berardi, R., Torniai, M., De Tursi, M., Grassadonia, A., Di Marino, P., Santini, D., Zeppola, T., Anesi, C., Gelibter, A., Occhipinti, M. A., Botticelli, A., Marchetti, P., Rastelli, F., Pergolesi, F., Tudini, M., Silva, R. R. & 5 others, Mallardo, D., Vanella, V., Ficorella, C., Porzio, G. & Ascierto, P. A., Nov 15 2019, In : Journal of Translational Medicine. 17, 1, 376.

Research output: Contribution to journalArticle

Corrosion inhibitors
Fatigue
Fatigue of materials
Neoplasms
Renal Cell Carcinoma
1 Citation (Scopus)

Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation–positive metastatic melanoma treated with vemurafenib ± cobimetinib

Lewis, K., Hauschild, A., Larkin, J., Ribas, A., Flaherty, K. T., McArthur, G. A., Dréno, B., McKenna, E., Zhu, Q., Mun, Y. & Ascierto, P. A., Jul 1 2019, In : European Journal of Cancer. 116, p. 45-55 11 p.

Research output: Contribution to journalArticle

Reducing Agents
Melanoma
Acids
Survival
GDC-0973
2 Citations (Scopus)

Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations

Trojaniello, C., Festino, L., Vanella, V. & Ascierto, P. A., Mar 4 2019, In : Expert Review of Clinical Pharmacology. 12, 3, p. 259-266 8 p.

Research output: Contribution to journalReview article

Melanoma
Mitogen-Activated Protein Kinase Kinases
Mutation
Disease-Free Survival
Disease Resistance

ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine Neuregulin

Ruggiero, C. F., Malpicci, D., Fattore, L., Madonna, G., Vanella, V., Mallardo, D., Liguoro, D., Salvati, V., Capone, M., Bedogni, B., Ascierto, P. A., Mancini, R. & Ciliberto, G., Sep 25 2019, In : Cancers. 11, 10

Research output: Contribution to journalArticle

Neuregulins
Circulating Neoplastic Cells
Cell- and Tissue-Based Therapy
Melanoma
Phosphorylation

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial

Lebbé, C., Meyer, N., Mortier, L., Marquez-Rodas, I., Robert, C., Rutkowski, P., Menzies, A. M., Eigentler, T., Ascierto, P. A., Smylie, M., Schadendorf, D., Ajaz, M., Svane, I. M., Gonzalez, R., Rollin, L., Lord-Bessen, J., Saci, A., Grigoryeva, E. & Pigozzo, J., Apr 10 2019, In : Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 37, 11, p. 867-875 9 p.

Research output: Contribution to journalArticle

Melanoma
Disease-Free Survival
Incidence
Survival
Therapeutics
3 Citations (Scopus)

First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis

Schilling, B., Martens, A., Geukes Foppen, M. H., Gebhardt, C., Hassel, J. C., Rozeman, E. A., Gesierich, A., Gutzmer, R., Kähler, K. C., Livingstone, E., Diamantopoulos, P. T., Gogas, H., Madonna, G., Ascierto, P. A., Goldinger, S. M., Mangana, J., Garbe, C., Schadendorf, D., Blank, C. & Weide, B., Jan 1 2019, In : Cancer Immunology, Immunotherapy.

Research output: Contribution to journalArticle

Melanoma
Death Domain Receptors
Survival
Mitogen-Activated Protein Kinases
Therapeutics

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., Ferrucci, P. F., Smylie, M., Hogg, D., Hill, A., Márquez-Rodas, I., Haanen, J., Guidoboni, M., Maio, M., Schöffski, P., Carlino, M. S. & 11 others, Lebbé, C., McArthur, G., Ascierto, P. A., Daniels, G. A., Long, G. V., Bastholt, L., Rizzo, J. I., Balogh, A., Moshyk, A., Hodi, F. S. & Wolchok, J. D., Oct 17 2019, In : The New England journal of medicine. 381, 16, p. 1535-1546 12 p.

Research output: Contribution to journalArticle

Melanoma
Survival
ipilimumab
nivolumab
Disease-Free Survival

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAFV600-mutated Metastatic Melanoma

Yan, Y., Wongchenko, M. J., Robert, C., Larkin, J., Ascierto, P. A., Dréno, B., Maio, M., Garbe, C., Chapman, P. B., Sosman, J. A., Shi, Z., Koeppen, H., Hsu, J. J., Chang, I., Caro, I., Rooney, I., McArthur, G. A. & Ribas, A., 2019, In : Clinical Cancer Research.

Research output: Contribution to journalArticle

Melanoma
Exome
Neoplasms
Programmed Cell Death 1 Receptor
Genes
2 Citations (Scopus)

Germline and somatic mutations in patients with multiple primary melanomas: A next generation sequencing study

Casula, M., Paliogiannis, P., Ayala, F., De Giorgi, V., Stanganelli, I., Mandalà, M., Colombino, M., Manca, A., Sini, M. C., Caracò, C., Ascierto, P. A., Satta, R. R., Dedola, M. F., Denti, S., Fedeli, M. A., Montesu, M. A., Profili, S., Scotto, T., Sini, G., Tanda, F. & 9 others, Lissia, A., Cossu, A., Palmieri, G., Ghiorzo, P., Queirolo, P., Quaglino, P., Botti, G., Sileni, V. C. & Di Giacomo, A. M., Aug 5 2019, In : BMC Cancer. 19, 1, 772.

Research output: Contribution to journalArticle

Open Access
Germ-Line Mutation
Melanoma
Mutation
Italy
Population

Health-related quality of life in patients with fully resected BRAFV600 mutation–positive melanoma receiving adjuvant vemurafenib

the BRIM8 Investigators, Dec 2019, In : European Journal of Cancer. 123, p. 155-161 7 p.

Research output: Contribution to journalArticle

Melanoma
Quality of Life
Health Status
Therapeutics
PLX4032

Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM

Lewis, K. D., Larkin, J., Ribas, A., Flaherty, K. T., McArthur, G. A., Ascierto, P. A., Dréno, B., Yan, Y., Wongchenko, M., McKenna, E., Zhu, Q., Mun, Y. & Hauschild, A., Jan 1 2019, In : British Journal of Cancer.

Research output: Contribution to journalArticle

Open Access
Survival
Disease-Free Survival
Melanoma
Genes
GDC-0973

Mutational concordance between primary and metastatic melanoma: A next-generation sequencing approach

Manca, A., Paliogiannis, P., Colombino, M., Casula, M., Lissia, A., Botti, G., Caracò, C., Ascierto, P. A., Sini, M. C., Palomba, G., Pisano, M., Dedola, M. F., Fedeli, M. A., Montesu, M. A., Rubino, C., Satta, R., Scotto, T., Sini, G., Maio, M., Massi, D. & 10 others, Anichini, A., Pfeffer, U., Doneddu, V., Cossu, A., Palmieri, G., Ghiorzo, P., Queirolo, P., Quaglino, P., Sileni, V. C. & Di Giacomo, A. M., Aug 28 2019, In : Journal of Translational Medicine. 17, 1, 289.

Research output: Contribution to journalArticle

Open Access
Melanoma
Genes
Tissue
Mutation
Literature

Mutational concordance between primary and metastatic melanoma: A next-generation sequencing approach

Manca, A., Paliogiannis, P., Colombino, M., Casula, M., Lissia, A., Botti, G., Caracò, C., Ascierto, P. A., Sini, M. C., Palomba, G., Pisano, M., Dedola, M. F., Fedeli, M. A., Montesu, M. A., Rubino, C., Satta, R., Scotto, T., Sini, G., Maio, M., Massi, D. & 10 others, Anichini, A., Pfeffer, U., Doneddu, V., Cossu, A., Palmieri, G., Ghiorzo, P., Queirolo, P., Quaglino, P., Sileni, V. C. & Di Giacomo, A. M., 2019, In : Journal of Translational Medicine. 17, 1

Research output: Contribution to journalArticle

Melanoma
Genes
Tissue
Mutation
Literature
2 Citations (Scopus)

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium

International Neoadjuvant Melanoma Consortium., Jul 1 2019, In : The Lancet Oncology. 20, 7, p. e378-e389

Research output: Contribution to journalReview article

Neoadjuvant Therapy
Melanoma
Translational Medical Research
Biomarkers
Anus Neoplasms

Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results

Sharma, P., Siefker-Radtke, A., de Braud, F., Basso, U., Calvo, E., Bono, P., Morse, M. A., Ascierto, P. A., Lopez-Martin, J., Brossart, P., Rohrberg, K., Mellado, B., Fischer, B. S., Meadows-Shropshire, S., Abdel Saci, Callahan, M. K. & Rosenberg, J., 2019, In : Journal of clinical oncology : official journal of the American Society of Clinical Oncology. p. JCO1900538

Research output: Contribution to journalArticle

Carcinoma
Platinum
Immunotherapy
Multicenter Studies
Disease Progression

Nivolumab for the treatment of small cell lung cancer

Simeone, E., Grimaldi, A. M., Festino, L., Trojaniello, C., Vitale, M. G., Vanella, V., Curvietto, M. & Ascierto, P. A., Jan 1 2019, (Accepted/In press) In : Expert Review of Respiratory Medicine.

Research output: Contribution to journalArticle

Small Cell Lung Carcinoma
Drug Therapy
Immunotherapy
Clinical Trials
Therapeutics

Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy)

Ascierto, P. A., Bifulco, C., Buonaguro, L., Emens, L. A., Ferris, R. L., Fox, B. A., Delgoffe, G. M., Galon, J., Gridelli, C., Merlano, M., Nathan, P., Odunsi, K., Okada, H., Paulos, C. M., Pignata, S., Schalper, K. A., Spranger, S., Tortora, G., Zarour, H., Butterfield, L. H. & 1 others, Puzanov, I., Nov 29 2019, In : Journal for ImmunoTherapy of Cancer. 7, 1, 1 p.

Research output: Contribution to journalReview article

Perspectives in melanoma: Meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy)

Ascierto, P. A., Agarwala, S. S., Botti, G., Budillon, A., Davies, M. A., Dummer, R., Ernstoff, M., Ferrone, S., Formenti, S., Gajewski, T. F., Garbe, C., Hamid, O., Lo, R. S., Luke, J. J., Michielin, O., Palmieri, G., Zitvogel, L., Marincola, F. M., Masucci, G., Caracò, C. & 2 others, Thurin, M. & Puzanov, I., Jul 22 2019, In : Journal of Translational Medicine. 17, 1, 234.

Research output: Contribution to journalArticle

Open Access
Italy
Tumors
Melanoma
Biomarkers
Neoplasms
1 Citation (Scopus)

Preanalytic Variables and Tissue Stewardship for Reliable Next-Generation Sequencing (NGS) Clinical Analysis

Ascierto, P. A., Bifulco, C., Palmieri, G., Peters, S. & Sidiropoulos, N., Sep 1 2019, In : Journal of Molecular Diagnostics. 21, 5, p. 756-767 12 p.

Research output: Contribution to journalReview article

Open Access
Neoplasms
Biomarkers
Precision Medicine
Routine Diagnostic Tests
Nucleic Acids
7 Citations (Scopus)

Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma

Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V. G., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M. S., Sandhu, S., Larkin, J., Puig, S., Ascierto, P. A., Rutkowski, P., Schadendorf, D., Koornstra, R., Hernandez-Aya, L., Di Giacomo, A. M., van den Eertwegh, A. JM. & 12 others, Grob, J. J., Gutzmer, R., Jamal, R., Lorigan, P. C., Lupinacci, R., Krepler, C., Ibrahim, N., Kicinski, M., Marreaud, S., van Akkooi, A. C., Suciu, S. & Robert, C., Jul 1 2019, In : European Journal of Cancer. 116, p. 148-157 10 p.

Research output: Contribution to journalArticle

Melanoma
Placebos
Recurrence
Neoplasms
Survival
5 Citations (Scopus)

Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations

Ascierto, P. A., Capone, M., Grimaldi, A. M., Mallardo, D., Simeone, E., Madonna, G., Roder, H., Meyer, K., Asmellash, S., Oliveira, C., Roder, J. & Grigorieva, J., Mar 29 2019, In : Journal for ImmunoTherapy of Cancer. 7, 1, 91.

Research output: Contribution to journalArticle

Proteomics
Melanoma
Mutation
Disease-Free Survival
Survival
3 Citations (Scopus)

Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma

Ottaviano, M., De Placido, S. & Ascierto, P. A., Jan 1 2019, In : Virchows Archiv.

Research output: Contribution to journalReview article

Melanoma
Neoplasms
Immune System
Merkel Cell Carcinoma
Carcinoma

Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma

Fattore, L., Ruggiero, C. F., Pisanu, M. E., Liguoro, D., Cerri, A., Costantini, S., Capone, F., Acunzo, M., Romano, G., Nigita, G., Mallardo, D., Ragone, C., Carriero, M. V., Budillon, A., Botti, G., Ascierto, P. A., Mancini, R. & Ciliberto, G., Jul 2019, In : Cell Death and Differentiation. 26, 7, p. 1267-1282 16 p.

Research output: Contribution to journalArticle

MicroRNAs
Drug Resistance
Melanoma
Recurrence
Mitogen-Activated Protein Kinase Kinases
1 Citation (Scopus)

Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)

Nathan, P., Ascierto, P. A., Haanen, J., Espinosa, E., Demidov, L., Garbe, C., Guida, M., Lorigan, P., Chiarion-Sileni, V., Gogas, H., Maio, M., Fierro, M. T., Hoeller, C., Terheyden, P., Gutzmer, R., Guren, T. K., Bafaloukos, D., Rutkowski, P., Plummer, R., Waterston, A. & 8 others, Kaatz, M., Mandala, M., Marquez-Rodas, I., Muñoz-Couselo, E., Dummer, R., Grigoryeva, E., Young, T. C. & Schadendorf, D., Sep 1 2019, In : European Journal of Cancer. 119, p. 168-178 11 p.

Research output: Contribution to journalArticle

Melanoma
Safety
Therapeutics
Skin
ipilimumab

Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab

(IMI), O. B. O. T. I. M. I., Pistillo, M. P., Fontana, V., Morabito, A., Dozin, B., Laurent, S., Carosio, R., Banelli, B., Ferrero, F., Spano, L., Tanda, E., Ferrucci, P. F., Martinoli, C., Cocorocchio, E., Guida, M., Tommasi, S., De Galitiis, F., Pagani, E., Antonini Cappellini, G. C., Marchetti, P. & 9 others, Quaglino, P., Fava, P., Osella-Abate, S., Ascierto, P. A., Capone, M., Simeone, E., Romani, M., Spagnolo, F. & Queirolo, P., 2019, In : Cancer Immunology and Immunotherapy.

Research output: Contribution to journalArticle

Melanoma
Biomarkers
ipilimumab
Survival Analysis
Serum

Survival Outcomes in Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma Treated with Nivolumab Therapy

Ascierto, P. A., Long, G. V., Robert, C., Brady, B., Dutriaux, C., Di Giacomo, A. M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., Savage, K. J., Hernberg, M. M., Lebbé, C., Charles, J., Mihalcioiu, C., Chiarion-Sileni, V., Mauch, C., Cognetti, F., Ny, L. & 8 others, Arance, A., Svane, I. M., Schadendorf, D., Gogas, H., Saci, A., Jiang, J., Rizzo, J. & Atkinson, V., 2019, In : JAMA oncology.

Research output: Contribution to journalArticle

Dacarbazine
Melanoma
Survival
Programmed Cell Death 1 Receptor
Age Groups

Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade

Jacquelot, N., Yamazaki, T., Roberti, M. P., Duong, C. P. M., Andrews, M. C., Verlingue, L., Ferrere, G., Becharef, S., Vétizou, M., Daillère, R., Messaoudene, M., Enot, D. P., Stoll, G., Ugel, S., Marigo, I., Foong Ngiow, S., Marabelle, A., Prevost-Blondel, A., Gaudreau, P. O., Gopalakrishnan, V. & 13 others, Eggermont, A. M., Opolon, P., Klein, C., Madonna, G., Ascierto, P. A., Sucker, A., Schadendorf, D., Smyth, M. J., Soria, J. C., Kroemer, G., Bronte, V., Wargo, J. & Zitvogel, L., 2019, In : Cell Research.

Research output: Contribution to journalArticle

Interferon Type I
Regulatory T-Lymphocytes
Nitric Oxide Synthase
Monoclonal Antibodies
Immunotherapy

The great debate at "immunotherapy Bridge 2018", Naples, November 29th, 2018

Ascierto, P. A., Butterfield, L. H., Demaria, S., Ferris, R. L., Freeman, G. J., Lo, R. S., Mantovani, A., Nathan, P., Hamid, O., Politi, K. & Puzanov, I., Aug 15 2019, In : Journal for ImmunoTherapy of Cancer. 7, 1, 221.

Research output: Contribution to journalReview article

Open Access
Immunotherapy
Neoplasms
Innate Immunity
Italy
Therapeutics

The great debate at "melanoma Bridge 2018", Naples, December 1st, 2018

Ascierto, P. A., Bruzzi, P., Eggermont, A., Hamid, O., Tawbi, H. A., Van Akkooi, A., Testori, A., Caracò, C., Puzanov, I. & Perrone, F., May 10 2019, In : Journal of Translational Medicine. 17, 1, 148.

Research output: Contribution to journalArticle

Open Access
CTLA-4 Antigen
Melanoma
Ligands
Pharmaceutical Preparations
Neoadjuvant Therapy
2 Citations (Scopus)

The potential of BRAF-associated non-coding RNA as a therapeutic target in melanoma

Fattore, L., Mancini, R., Ascierto, P. A. & Ciliberto, G., Jan 2 2019, In : Expert Opinion on Therapeutic Targets. 23, 1, p. 53-68 16 p.

Research output: Contribution to journalArticle

Untranslated RNA
Melanoma
Deregulation
Expert Testimony
Therapeutics
1 Citation (Scopus)

The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era

Vanella, V., Festino, L., Trojaniello, C., Vitale, M. G., Sorrentino, A., Paone, M. & Ascierto, P. A., Sep 1 2019, In : Current Oncology Reports. 21, 9, 76.

Research output: Contribution to journalReview article

Immunotherapy
Melanoma
Therapeutics
Mitogen-Activated Protein Kinase Kinases
Standard of Care

Toward a comprehensive view of cancer immune responsiveness: A synopsis from the SITC workshop

Bedognetti, D., Ceccarelli, M., Galluzzi, L., Lu, R., Palucka, K., Samayoa, J., Spranger, S., Warren, S., Wong, K. K., Ziv, E., Chowell, D., Coussens, L. M., De Carvalho, D. D., Denardo, D. G., Galon, J., Kaufman, H. L., Kirchhoff, T., Lotze, M. T., Luke, J. J., Minn, A. J. & 34 others, Politi, K., Shultz, L. D., Simon, R., Thórsson, V., Weidhaas, J. B., Ascierto, M. L., Ascierto, P. A., Barnes, J. M., Barsan, V., Bommareddy, P. K., Bot, A., Church, S. E., Ciliberto, G., De Maria, A., Draganov, D., Ho, W. S., McGee, H. M., Monette, A., Murphy, J. F., Nisticò, P., Park, W., Patel, M., Quigley, M., Radvanyi, L., Raftopoulos, H., Rudqvist, N. P., Snyder, A., Sweis, R. F., Valpione, S., Butterfield, L. H., Disis, M. L., Fox, B. A., Cesano, A. & Marincola, F. M., May 22 2019, In : Journal for ImmunoTherapy of Cancer. 7, 1, 131.

Research output: Contribution to journalReview article

Open Access
Immunotherapy
Education
Neoplasms
Advisory Committees
Allergy and Immunology